Isis Pharma $ISIS held its annual research and development pipeline update for analysts and investors on January 5, 2012. Unfortunately there was no question and answer session, but I’ll review some of the highlights from the two hours of prepared remarks below. An overview of 2012 goals and milestones for the entire antisense pipeline was […]
ACHN & ARIA – Time To Take Some Profits
Both Achillion and Ariad hit 52-week highs today after running up on positive news. While we continue to believe the companies will be successful, we also believe the stocks are getting fairly expensive and think it is a good time to take profits. Since recommending ARIA on November 10th at $10.72, it has gained 31.25% […]
Upcoming FDA Decisions and Advisory Panels
To help save everyone some time, we went ahead and rounded up the upcoming FDA PDUFA dates and FDA Advisory Committees. We will have trade ideas and opinions on some of these events in the near future. We have highlighted some of those which we feel are the biggest importance to the market with asterisks(*). […]
VVUS – Quick Update – Vivus alters NDA for Qnexa, changes REMS
Vivus Pharmaceuticals (NASDAQ:VVUS) reached an agreement today with the FDA, to alter both it’s REMS and Label for obesity drug candidate, Qnexa. Previous Proposed Label Management took a very conservative approach when filing the initial NDA. Given questions about teratogencity of topiramate, one of the active ingredients in Qnexa, Vivus’s management proposed a label that […]
BMY & INHX – Bristol-Myers Squibb Buys Inhibitex for $2.5 Billion
Bristol-Myers Squibb Buys Inhibitex for $2.5 Billion On Saturday, Bristol announced it would acquire Inhibitex for $26 a share, about $2.5 billion dollars, a 163% premium to the companies $9.87 Friday closing price. Inhibitex had been the hot topic of takeover speculation lately for its HCV drug INX-189, a coveted nucleotide polymerase inhibitor. The hepatitis […]
ACHN & INHX: Two HCV Drugmakers In The Spotlight
ACHN v. INHX: Two HCV Drugmakers In The Spotlight Achillion: On Wednesday January 4, Achillion announced it had received Fast-Track designation from the FDA for its experimental HCV drug ACH-1625. A positive development for sure- investors reacted by lifting the stock 1% on a mostly down day for biotechs. Fast Track status is reserved for […]
Biotech catalysts at two upcoming medical conferences
We want to take a moment to highlight two upcoming oncology focused medical conferences that will showcase data that represent potential catalysts for several biotech companies we’re tracking. First up, we have the 2012 ASCO Gastrointestinal Cancers Symposium from January 19-21, 2012. This conference will be focused on developments in the treatment of cancers of […]
AMRN – Will AMR101 receive New Chemical Entity (NCE) Status from the FDA?
Why does this question of New Chemical Entity (NCE) status matter? Simply put, if AMR101 is designated as a New Chemical Entity (NCE) by the FDA, the product receives five years of market exclusivity after approval in the United States, regardless of the patent situation (sometimes referred to as Hatch-Waxman exclusivity). During this time the FDA will […]
AVEO – Quick take on top-line data
AVEO Pharmaceuticals(NASDAQ: AVEO) kicked off the 2012 trading year with news from their Phase 3 trial, TIVO-1. AVEO announced that Tivozanib had demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of Tivozanib compared to Nexavar(sorafenib) in patients […]
POZN – Interview With POZN CEO John Plachetka and COO Liz Cermak
Interview With POZN CEO John Plachetka and COO Liz Cermak After seeing its shares slide for much of the year, Pozen stock jumped 46% when it struck a deal to sell the right to its royalties from the migraine drug Treximate to CPPIB Credit Investments Inc. for $75 million. Pozen will now end the year […]
AIS – “Lies, Damn Lies, and Statistics”
Anatres Pharma (AIS) has been the subject of biotech stock buzz lately, due to two closely spaced news events concerning the company’s proprietary topical gel products. The failure of LibiGel, a testosterone product for female sexual dysfunction, in phase 3 efficacy trials conducted by their partner BioSante Pharma (BPAX), has grabbed the headlines. While that […]
MITI – Initiate Coverage
Micromet: Initiate Coverage Background: Micromet specializes in the development of cancer drugs based on a new class of therapeutics called “bispecific antibodies.” These novel antibodies are capable of recognizing and binding two different antigens and have been termed “bispecific T-cell engagers” or BiTE antibodies. Bispecific antibodies are part of a new generation of more advanced […]
VRUS – Pharmasset Halts Trial- And The Winner Is…
Pharmasset, a leader in the development of next generation HCV treatments, took a stumble today as it announced the halt of all trials involving its drug PSI-938 due to possible liver toxicities. This compound is the second of Pharmasset’s two nucleotide analog polymerase inhibitors (nuc) and further behind in the clinic. The more advanced compound, […]
VVUS – Vivus Pharmaceuticals – Initiating Covereage – Neutral
Vivus (VVUS), is a specialty pharmaceutical company with two lead product candidates that are facing a regulatory decision within the next 6 months. Besides two PDUFA dates, VVUS also has an FDA Advisory Committee Meeting and results from a key study, dubbed FORTRESS, due out in the coming days. The most anticipated drug candidate […]
AVEO – Initiating Coverage
Overview AVEO Pharmaceuticals(NASDAQ: AVEO) is a clinical stage cancer therapeutics company with 2 main compounds in development. AVEO’s lead candidate, Tivozanib(AV-951), is designed to block the VEGF pathway by inhibiting all three VEGF receptors(1,2,3). Tivozanib is currently being tested in a pivotal Phase 3 clinical trial called TIVO-1, which is comparing Tivozanib to Onyx’s sorafenib […]
YMI – ASH 2011 Update
YM Bioscience stock surged in after hours trading following their presentation of results from an ongoing multi-center Phase I/II study of the JAK1/2 inhibitor CYT387 for the treatment of Myelofibrosis (MF) at ASH Monday afternoon. Shares jumped to as high as $2.04 in after-hours trading before settling to $1.69 Tuesday. It has since fallen to […]
BPAX – Picking up the pieces
After much anticipation, BioSante Pharma $BPAX released top-line data for the two pivotal phase 3 efficacy data for LibiGel, a testosterone gel for the treatment of hypoactive sexual desire disorder (HSDD) on December 14, 2011. Quite simply, the results were disastrous. LibiGel failed to show a significant improvement in the number of satisfying sexual events (SSEs) or sexual […]
INCY – ASH Update: Incyte’s JAK1/2 Inhibitor
ASH Update: Incyte’s JAK1/2 Inhibitor By Patrick Crutcher and Jason Chew On Saturday December 10, we took to the floors of the San Diego Convention Center for the opening rounds of ASH presentations. Today’s focus was mainly on the poster sessions with presenters manning their stations beginning at 5pm. The item we were most interested […]
SPPI – Generic Fusilev fears cause sell-off
Spectrum Pharma $SPPI shares were lower by as much as 10% on Friday 12/9/2011 based on concerns over potential generic competition for their cancer drug Fusilev (levoleucovorin). A flurry of media interviews by management and a press release defending Fusilev’s patent protection helped the stock recover part of its losses by the market close. Fusilev, […]
